Astrazeneca (AZN) Payables (2009 - 2026)

Astrazeneca's Payables history runs 18 years deep, the most recent figure standing at -$22.6 billion for Q1 2026.

• In Q1 2026, Payables rose 4.01% year-over-year to -$22.6 billion; the TTM figure through Mar 2026 stood at -$22.6 billion (up 4.01% YoY), while the FY2025 annual figure was -$25.3 billion, down 212.88% from the prior year.
• Payables was -$22.6 billion for Q1 2026 at Astrazeneca, up from -$25.3 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $22.4 billion in Q4 2024 to a low of -$25.3 billion in Q4 2025.
• Historically, Payables has averaged -$14.7 billion across 5 years, with a median of -$19.9 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Payables jumped 777.41% in 2023, then slumped 212.88% in 2025.
• A 5-year view of Payables shows it stood at $2.6 billion in 2022, then surged by 777.41% to $22.4 billion in 2023, then rose by 0.14% to $22.4 billion in 2024, then plunged by 212.88% to -$25.3 billion in 2025, then climbed by 10.84% to -$22.6 billion in 2026.
• The last three Payables figures came in at -$22.6 billion (Q1 2026), -$25.3 billion (Q4 2025), and -$25.1 billion (Q3 2025), per Business Quant data.